Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, T-Cell 5Recurrence 2Lymphoma, T-Cell, Peripheral 2Lymphoma 2Immunoblastic Lymphadenopathy 2Sezary Syndrome 1Mycosis Fungoides 1Lymphoma, Large-Cell, Anaplastic 1Leukemia, Prolymphocytic, T-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Large Granular Lymphocytic 1Enteropathy-Associated T-Cell Lymphoma 1

Interventions

Specimen Handling 4Cyclophosphamide 4Biopsy 4Radiotherapy 3Nivolumab 3Magnetic Resonance Spectroscopy 3sodium-iodide symporter 2pembrolizumab 2mogamulizumab 2fludarabine phosphate 2fludarabine 2cemiplimab 2X-Rays 2Whole-Body Irradiation 2Tacrolimus 2Photons 2Peripheral Blood Stem Cell Transplantation 2Mycophenolic Acid 2Immunoglobulin G 2Disulfides 2Busulfan 2Brentuximab Vedotin 2talimogene laherparepvec 1ruxolitinib 1hypericin 1duvelisib 1Vorinostat 1Transplantation 1Sirolimus 1Radiation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mycosis Fungoides × duvelisib × 90 days × Clear all
NCT04652960 2026-05-13

Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome

National Cancer Institute (NCI)

Phase 1 Active not recruiting
38 enrolled
Lymphoid

Mycosis Fungoides, Sezary Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡